Clinical outcomes by baseline metastases in patients with renal cell carcinoma treated with lenvatinib plus pembrolizumab versus sunitinib: Post hoc analysis of the CLEAR trial

Gastrointestinal Cancer

Biomarker analyses from the phase 3 randomized CLEAR trial: Lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma

Ann Oncol

Motzer RJ, Porta C, Eto M, Hutson TE, Rha SY, Merchan JR, Winquist E, Gurney H, Grünwald V, George S, Markensohn J, Burgents JE, Cristescu R, Sachdev P, Narita Y, Huang J, Zhao Z, Okpara CE, Minoshima Y, Choueiri TK

doi: 10.1016/j.annonc.2024.12.003

Genitourinary Cancer

The incidence of immune-related adverse events (irAEs) and their association with clinical outcomes in advanced renal cell carcinoma and urothelial carcinoma patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis

Cancer Treat Rev

Zhang Y, Chen J, Liu H, Dai J, Zhao J, Zhu S, Zhang X, Liang J, Hu X, Zhao J, Liu Z, Shen P, Sun G, Zeng H

doi: 10.1016/j.ctrv.2024.102787

Genitourinary Cancer

Health-related quality of life with belzutifan versus everolimus for advanced renal cell carcinoma (LITESPARK-005): patient-reported outcomes from a randomised, open-label, phase 3 trial

Lancet Oncol

Powles T, Choueiri TK, Albiges L, Peltola K, de Velasco G, Burotto M, Suarez C, Ghatalia P, Iacovelli R, Lam ET, Verzoni E, Gümüş M, Stadler WM, Kollmannsberger C, Melichar B, Venugopal B, Gross-Goupil M, Poprach A, De Santis M, Rizzo M, Shinde R, Saretsky TL, He L, Perini RF, Vickery D, Rini B

doi: 10.1016/S1470-2045(25)00032-4

Genitourinary Cancer

Avelumab + axitinib vs sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase 3 JAVELIN Renal 101 trial

Ann Oncol

Choueiri TK, Penkov K, Uemura H, Campbell MT, Pal S, Kollmannsberger C, Lee JL, Venugopal B, van den Eertwegh AJM, Negrier S, Gurney H, Albiges L, Berger R, Haanen JBAG, Oyervides Juárez V, Rini BI, Larkin J, Nolè F, Schmidinger M, Atkins MB, Tomita Y, Ellers-Lenz B, Hoffman J, Sandner R, Wang J, di Pietro A, Motzer RJ

doi: 10.1016/j.annonc.2024.12.008

COMMENTED

Genitourinary Cancer

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial

★ 1 Recommended and commented by Prof. Dr Richard Cathomas, Faculty Member

Ann Oncol

Tannir NM, Albigès L, McDermott DF, Burotto M, Choueiri TK, Hammers HJ, Barthélémy P, Plimack ER, Porta C, George S, Donskov F, Atkins MB, Gurney H, Kollmannsberger CK, Grimm MO, Barrios C, Tomita Y, Castellano D, Grünwald V, Rini BI, Jiang R, Desilva H, Federov V, Lee CW, Motzer RJ

doi: 10.1016/j.annonc.2024.07.727

Genitourinary Cancer

Treatment options in first-line metastatic renal carcinoma: A meta-analysis of 2556 patients treated with immune checkpoint inhibitors-based combinations in randomised controlled trials

Cancer Treat Rev

Tucci M, Mandarà M, Giuliani J, Durante E, Buttigliero C, Turco F, Palesandro E, Campisi I, Singh N, Muraro M, Munoz F, Fiorica F

doi: 10.1016/j.ctrv.2024.102745

Genitourinary Cancer

Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study

Lancet

Choueiri TK, Albiges L, Barthélémy P, Iacovelli R, Emambux S, Molina-Cerrillo J, Garmezy B, Barata P, Basu A, Bourlon MT, Moon H, Ratta R, McKay RR, Chehrazi-Raffle A, Hammers H, Heng DYC, Braendle E, Beckermann KE, McGregor BA, Motzer RJ

doi: 10.1016/S0140-6736(24)01758-6

Multiple Myeloma (MM)

Characteristics and outcomes in patients with lenalidomide-refractory multiple myeloma treated with 1-3 prior lines of therapy: Analysis of individual patient-level data from daratumumab clinical trials

Eur J Cancer

Yong K, Einsele H, Schecter JM, Roccia T, Deraedt W, Lendvai N, Slaughter A, Lonardi C, Connors K, Qi K, Londhe A, Carson R, Kharat A, Cost P, Valluri S, Mendes J, Pacaud L, Patel N, Florendo E, Dhakal B

doi: 10.1016/j.ejca.2024.115157

Breast Cancer

Patient-Reported Outcomes for Low-Risk Ductal Carcinoma In Situ: A Secondary Analysis of the COMET Randomized Clinical Trial

JAMA Oncol

Partridge AH, Hyslop T, Rosenberg SM, Bennett AV, Drier S, Jonsson M, Shimada A, Li Y, Li Y, Lynch T, Frank E, Collyar D, Basila D, Pinto D, Weiss A, Wolf A, Norris K, Witten M, Boisvert M, Giuliano A, Larson KE, Yost K, McAuliffe PF, Krie A, Tamirisa N, Darai S, Carey L, Thompson A, Hwang ES, COMET Study Consortium

doi: 10.1001/jamaoncol.2024.6556

Related content

Biomarker analyses from the phase 3 randomized CLEAR trial: Lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma

The incidence of immune-related adverse events (irAEs) and their association with clinical outcomes in advanced renal cell carcinoma and urothelial carcinoma patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis

Health-related quality of life with belzutifan versus everolimus for advanced renal cell carcinoma (LITESPARK-005): patient-reported outcomes from a randomised, open-label, phase 3 trial

Avelumab + axitinib vs sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase 3 JAVELIN Renal 101 trial

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial

Treatment options in first-line metastatic renal carcinoma: A meta-analysis of 2556 patients treated with immune checkpoint inhibitors-based combinations in randomised controlled trials

Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study

Characteristics and outcomes in patients with lenalidomide-refractory multiple myeloma treated with 1-3 prior lines of therapy: Analysis of individual patient-level data from daratumumab clinical trials

Patient-Reported Outcomes for Low-Risk Ductal Carcinoma In Situ: A Secondary Analysis of the COMET Randomized Clinical Trial